Davis Polk is advising China Cinda Asset Management Co., Ltd. (“China Cinda”) in connection with a proposed strategic investment by Sino Biopharmaceutical Limited. Pursuant to terms of the investment, China Cinda has conditionally agreed to issue H shares to Sino Biopharmaceutical for an aggregate consideration of approximately RMB4.92 billion. The investment, which is subject to a number of conditions precedent, will give Sino Biopharmaceutical approximately 4.999% interest in the total share capital of China Cinda.

China Cinda is an asset management company in China whose H shares are listed on the Hong Kong Stock Exchange. It is principally engaged in distressed asset management and provides customized financial solutions and differentiated asset management services to its clients through the synergistic operation of its diversified business platforms. Sino Biopharmaceutical is a company incorporated in the Cayman Islands with limited liability, which is principally engaged in the research, development, production and sale of a series of modernized Chinese medicines and chemical medicines for the treatment of hepatitis and cardio-cerebral diseases.

The Davis Polk team includes partner Antony Dapiran and associates Yang Chu and Patrick Peng. All members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post